Pilot study of duloxetine for cancer patients with neuropathic pain non-responsive to pregabalin
Anticancer Research,  Clinical Article

Matsuoka H et al. – Duloxetine administration may be effective for neuropathic pain in cancer patients who cannot tolerate pregabalin administration.

Methods
  • The subjects of the study were 15 cancer patients with neuropathic pain who visited the Kinki University Faculty of Medicine Hospital and met the International Association for the Study of Pain diagnostic criteria for neuropathic pain.
  • Duloxetine was administered to patients in whom pregabalin could not be administered.
  • The influence of duloxetine was investigated retrospectively with the use of a numerical rating scale.

Results
  • Pain was reduced in 7 out of the 15 patients.
  • Sleepiness and the light–headed feeling were improved in four patients, in whom, however, the pain was not reduced.
  • Thus, duloxetine was judged to be effective in 11 patients.
  • The maintenance dose of duloxetine was 20–40 mg/day.

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

    Currently, there are no available articles.

Your Unread Messages in Family Medicine

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Family Medicine Articles

Indexed Journals in Family Medicine: American Family Physician, Archives of Family Med, Annals of Family Medmore

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Connect with us, stay current.

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Close